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Introduction
Hypertension is a rapidly moving clinical field with frequent
developments in new pharmacologic agents and management
strategies. Perhaps more importantly, there have been
substantial improvements in our understanding of how best to
use the drugs available to us. In this article, I will review some
of the more important advances in our understanding of
hypertension over the past two years, specifically by reviewing
six important trials, one survey and two sets of guidelines, all
published between January 2002 and June 2004.
ARB – a better blood-pressure drug
A huge study (LIFE), involving more than 800 clinical
centres in Scandinavia, the UK and USA, compared the
angiotensin receptor blocker (ARB) losartan and the beta-
blocker atenolol as part of treatment for people with high BP
(sitting BP, 160-200/95-115 mmHg) and left ventricular
hypertrophy (LVH ascertained by electrocardiography).1,3  This
double-blind trial looked at 9193 patients aged 55 to 80 years;
54% were female, 92% white, 13% diabetic, and 8 and 16%
having a history of cerebrovascular and coronary artery disease
respectively. BP at baseline was closely matched, and at the end
of the study, it was reduced by 30.2 / 16.6 mmHg in the losartan
group and 29.1 / 16.8 mmHg in the atenolol group. More than
half of both groups received concomitant hydrochlorothiazides
and other antihypertensive agents as needed to achieve goal
BP of less than 140/90 mmHg. . Mean daily doses for losartan
and atenolol were 82 mg and 79 mg respectively.  During follow-
up (mean, 4.8 years), after adjusting for differences in achieved
BP levels, the incidence of the primary composite end-point
(cardiovascular death, myocardial infarction - MI, or stroke)
was lower with losartan than atenolol (11% vs 13%, P = 0.021).
Most of the benefit was driven by a 25% reduction in the risk of
fatal and non-fatal stroke (P = 0.001), with no benefit seen for
fatal or non-fatal MI, cardiovascular death and all-cause
mortality. Moreover, new-onset diabetes was less common (25%
reduction) with losartan. In addition, losartan was better
tolerated and caused greater regression of ECG-LVH than
atenolol. LIFE also looked at two prespecified groups: patients
with diabetes and patients with isolated systolic hypertension.
In diabetics (n =1195), losartan fared significantly better than
atenolol regarding the primary composite end-point (p = 0.03),
all-cause mortality (p = 0.002), cardiovascular mortality (p =
0.028), and admission for heart failure (P = 0.019). MI and
stroke rates were not different between the two treatment arms
in diabetics. In patients with isolated systolic hypertension (n
= 1326), losartan also reduced the rate of stroke and
cardiovascular deaths more than did atenolol.
In summary, these studies demonstrate that angiotensin-
receptor blockade is more effective and better tolerated than
beta-adrenergic receptor blockade for the treatment of
hypertension in the high-risk group of patients with LVH.
Diuretics best for high blood pressure
The largest hypertension clinical trial ever conducted
(ALLHAT) was a randomised, double-blind trial designed to
compare the rate of coronary heart disease (CHD) events in
‘high-risk’ hypertensive patients initially randomized to a
diuretic (chlorthalidone) vs each of three ‘alternative’
antihypertensive drugs: an alpha-adrenergic blocker
(doxazosin), an ACE-inhibitor (lisinopril) and a calcium-channel
blocker (CCB) (amlodipine), as well as the effects of lipid
lowering therapy in these individuals.4 Eligible patients were
aged 55 years or over with hypertension and with at least one
other CHD risk factor (previous MI or stroke, LVH by ECG or
echocardiogram, diabetes mellitus, current cigarette smoking,
and low HDL cholesterol levels). The original trial population
comprised of 42,418 patients, but the doxazosin arm of the trial
was stopped prematurely in January 2000 because of a 25%
higher rate of combined cardiovascular events and a twofold
higher rate of admission for heart failure (HF) compared with
chlothalidone. The remaining 33,357 patients stayed on their
study drugs until the end of the study. Of these, 15,255 were
randomized to chlorthalidone (12.5 – 25.0 mg/day), 9048 to
amlodipine (2.5 – 10.0 mg/day), and 9054 to lisinopril (10-40
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mg /day). If BP was not controlled to below 140/90 mmHg after
dose optimization with the study drug, open-label drugs
(atenolol, clonidine or reserpine as step 2 and hydrallazine as
step 3) could be added at the physician’s discretion. The mean
age of participants was 67 years; 47% were women, 35% were
black and 36% were diabetic. After a mean follow-up of 4.9 years,
primary outcome (fatal CHD and non-fatal MI) events occurred
in 2956 patients, with virtually identical frequencies in each of
the three treatment groups (6-year rates of 11.5%, 11.4% and
11.3% in the diuretic, ACE inhibitor and CCB respectively).
Likewise, all-cause mortality was not different between the three
groups. Differences were noted in secondary outcomes however.
Compared with those taking chlorthalidone, patients on
amlodipine had on average 0.8 mmHg higher systolic BP, 38%
higher risk of developing HF (P < 0.001), and 35% higher risk
of hospitalization or fatal HF (P < 0.001). Interestingly, lisinopril
appeared to be worse than chlothaildone – those taking lisinopril
had on average about a 2 mmHg higher follow-up systolic BP,
15% higher risk of stroke (P < 0.02), and a higher risk of
combined cardiovascular disease (p<0.001) with 11% higher risk
of hospitalization or treated angina (P = 0.01%) as well as 10%
higher risk of coronary revascularization (P = 0.05). Rather
surprisingly, patients on lisinopril also had a 19% higher risk of
developing HF (P<0.001).
In summary, thiazide-type diuretics are superior to ACE-
inhibitors or CCBs in preventing major cardiovascular disease
events. They are also less expensive. Therefore, thiazide diuretics
should be preferred first-line treatment for hypertension, If BP
control is inadequate after first-line treatment with another
agent, a thiazide should be the preferred second step.
Study clouds hypertension drug debate
The ANBP2 (Australian National Blood Pressure Study - 2)
appeared to contradict the above-mentioned ALLHAT trial.5
This open-label trial enrolled 6083 patients (51% female) aged
64 to 84 years, with hypertension being treated by family
practitioners. Overall, participants in ANBP-2 were more active
and had fewer major risk factors for CHD than the ALLHAT
population. Patients received either a diuretic or an ACE
inhibitor as the initial recommended drug; the choice of the
specific agent and dose was made by the family practitioners.
At the end of the five-year study period, BP had decreased by
26/12 mmHg from baseline in each group. 58% of patients
randomly assigned to the ACE-inhibitor group and 62% of those
assigned to the diuretics group were still receiving the assigned
treatment. The rate of the composite outcome (all cardiovascular
events and all-cause mortality per 1000 patient-years) was lower
in patients among patients on ACE-inhibitors (56.1) than in
those who were allocated to the diuretics group (59.8) (P = 0.05).
The difference in outcome was most pronounced among elderly
men. Overall rates of CHD, stroke and HF were the same in
both groups.
In summary, an ACE-inhibitor was more effective than a
thiazide diuretic in this active, elderly population. In an editorial
accompanying the study, it was pointed out that the apparently
contradictory findings from the ALLHAT trial might be
explained by ethnic differences among the two study
populations. Whites made up 95% of the Australian study group
whereas 35% of ALLHAT participants were blacks. Blacks are
known to respond better to diuretics than other classes of
hypertension drugs. One should also note that the rate of
abandoning allocated therapy in the ANBP2 study was quite
large (about 30% in each group).
Don’t forget lifestyle recommendations
In the PREMIER trial 6, the question was: In persons with
above-optimal BP, what is the relative effectiveness of two
behavioral interventions (established lifestyle recommendations
[ELR] and ELR plus the Dietary Approaches to Stop
Hypertension [DASH] diet) compared with advice only? ELR
meant weight loss for overweight participants, reduced sodium
intake, increased physical activity, and limited alcohol intake.
The DASH diet meant reduced fat and cholesterol and increased
potassium, calcium, magnesium, protein and fibre through
consumption of fruit, vegetables and low-fat dairy products. 810
generally healthy adults were recruited from four clinical centres
in the US. Mean age was 50 years, 62% were women, and all
had above-optimal BP (mean systolic BP 120-159 mmHg and
diastolic BP 80-95 mmHg during three screening visits).
Exclusion criteria were use of drugs affecting BP, target organ
damage, diabetes, previous cardiovascular event, cancer and
pregnancy. The ELR and the ELR+DASH groups had 14 group
meetings and 4 individual counseling sessions during the initial
six months. Patients in the advice group had a single 30-minute
individual session with a dietician. With regards to outcome,
patients in the behavioral intervention groups had significantly
greater reductions in systolic and diastolic BP than did patients
in the advice group. For example, mean between-group
differences in systolic BP were -3.7mmHg (ELR vs advice) and
-4.3mmHg (ELR + DASH vs advice).
In summary the nonsignificant differences between the
behavioral groups suggest that clinicians should focus on
promoting weight loss (averaged 5 kg in the study) through
caloric restriction and exercise: lifestyle measures, primarily
weight loss, lowers blood pressure.
A third of American adults have
high blood pressure
In an update of the National Health and Nutrition
Examination Survey (NHANES), researchers noted the first
overall increase in hypertension disease prevalence - 4% - after
three decades of declining rates. 7 Overall, almost a third (29%)
of the study participants were hypertensive – defined as having
a BP of 140/90 or higher or reported use of antihypertensive
drugs. In both past NHANES studies, the prevalence rate was
25%. Based on data from nearly 5500 Americans over age 18
examined from 1999 to 2000, researchers made estimates on
how BP affected the general population. Data was compared
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with previous NHANES studies involving some 9,900 people
in 1988-1991 and 9,700 in 1991-1994. Other survey findings
included an increase in disease rates in seniors of nearly 8%
such that now, two out of three of those over age 60 have high
BP compared with 58% in 1988. Regarding ethnic groups, about
34 % of blacks were afflicted, compared with 29% of whites and
21% of Hispanics. About 30% of people with high BP were
unaware of their hypertension and 42% of people in the study
with high blood pressure were not being treated for it.
In summary, contrary to early reports, hypertension
prevalence is increasing in the US. Hypertension control rates,
although improving, continue to be low. Programmes targeting
hypertension prevention and treatment remain of utmost
importance.
The new normal in high blood pressure
New USA federal guidelines on high blood pressure defined
a new prehypertension category defined as systolic BP 120 –
139 mmHg or diastolic BP 80 –89 mmHg.8 The new category
includes about 45 million people (22% or nearly 1 in 4 adults in
the USA) who once thought they had normal BP and who now,
based on the JNC 7 report, are being urged to make lifestyle
modifications to lower or prevent BP. The guidelines quote
research that show that by the age of 55 years, men and women
who do not already have high BP have a 90% chance of
developing it later. Systolic hypertension is recognized as a more
important cardiovascular risk factor than its diastolic
counterpart in those aged 50 years or older. In addition, the
risk of death due to MI and stroke increases rapidly with rising
BP levels, starting at levels as low as 115/75 mmHg. For every
20/10 mmHg rise in BP above this level, the risk of death from
cardiovascular disease doubles. The new guidelines state that
diuretics should be used as first-line treatment for most people
with high BP without other risk factors such as heart failure,
history of MI, diabetes, or kidney disease. The report calls for
more aggressive treatment of the condition through the use of
a combination of BP lowering medications; acknowledges that
most people with hypertension will require two or more drugs
to achieve goal BP of 140/90 or less, and exhorts that the goal
BP in people with kidney disease and diabetes should be less
than 130/80 mmHg.
The importance of overall cardiovascular
risk assessment
The new European guidelines (ESH-ESC) guidelines have
retained previous cut-off levels to define various grades of
hypertension, but emphasize that the real threshold for
hypertension depends on an individual patient’s total
cardiovascular risk profile. The guidelines explain how to assess
a patient’s risk according to the presence or absence of additional
risk factors, such as target-organ damage, and provide an
algorithm for the initiation of treatment.9  According to the
guidelines, full assessment of cardiovascular risk would require
formal diagnosis, after at least three separate BP measurements,
an ECG, measurement of abdominal circumference, plasma
creatinine, lipids, glucose and using a high-sensitivity assay, C-
reactive protein. In contrast with JNC 7, the European guidelines
do not use the term prehypertension, although they identify BP
in the range of 130-9/85-9 mmHg as ‘high normal’ BP. The
report then recommends that people with ‘high normal’ BP
initiate lifestyle measures, have other risk factors corrected and,
if cardiovascular risk is high, start antihypertensive treatment.
This approach is consistent with that recommended in the JNC
7 indicating that this difference relates more to style than
substance. The European guidelines categorize the BP in the
range 120-9/81-4 mmHg as normal though not optimal.
Therefore, it is really within these values that the approach to
BP classification differs across the Atlantic. Therapy should be
initiated either with a low dose of a single drug or a low-dose
combination of two drugs. The guidelines point out that, in
general, the five main classes of antihypertensive drugs
(diuretics, beta blockers, CCBs, ACE-inhibitors, and ARBs) are
all suitable for initiating and maintain therapy, except in certain
defined conditions, favouring or contraindicating use. For
example, ACE-inhibitors are favoured for use in post-MI, heart
failure, left ventricular dysfunction, nondiabetic and diabetic
nephropathy, and proteinuria,
Calcium channel blocker or beta blocker
in hypertensive CAD?
In a large 14-country open-label trial, called INVEST, 22,576
patients with hypertension and coronary artery disease, aged
50 years or older, were assigned either a CCB (sustained-release
verapamil) or a beta-blocker (atenolol).10  If needed, the ACE -
inhibitor trandolapril and hydrochlothiazide were added (in that
order) in the verapamil group, and hydrochlorthiazide and
trandolapril were added (in that order) in the atenolol group.
However, the ACE-inhibitor was added immediately for patients
in both groups who had diabetes, renal impairment or heart
failure. At 24 months, most patients in both groups were
receiving ACE-inhibitors, and half were receiving at least three
hypertension drugs. During a mean follow-up of 2.7 years, no
differences were found between the two groups in a combined
endpoint (death, nonfatal MI, or nonfatal stroke) or in any
individual endpoints. BP control and side effect profiles were
similar in the two groups. In summary, in patients with coronary
artery disease and hypertension, initial therapy with a CCB or
with a beta-blocker yielded similar outcomes.
The case for aggressive initial therapy
The VALUE study was designed to determine whether, for
the same level of BP reduction, valsartan, an ARB, would be
more cardioprotective than the CCB, amlodipine.11  In this large
trial, 15,245 hypertensive patients aged 50 years or older at risk
for cardiovascular complications were randomized into either
the CCB-based or the ARB- based regimens.  Mean age was 67.2
years, 32% were diabetic, 46% had a history of coronary artery
disease and 20% had a history of cerebrovascular disease.
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Patients were randomized to once daily treatment with valsartan
80 mg or amlodipine 5 mg, titrated to 160mg or 10 mg
respectively. If not at goal BP, hydrochlorthiazide was added
first at 12.5mg then at 25 mg. While the VALUE trial
demonstrated better BP control compared to other large scale
studies, 40% of patients in this high risk population did not
achieve the predefined BP goal of 140/90 mmHg or less.  With
respect to the incidence of the primary endpoint of cardiac
mortality and morbidity, there was no difference (p = 0.81)
between valsartan (10.6%) and amlodipine (10.4%). Likewise,
all-cause death rates were similar (11% valsartan versus 10.8%
amlodipine; p = 0.45). The two treatment regimens effectively
lowered BP but unintentionally, early in the trial, BP was
lowered more with amlodipine than with valsartan. These
unintended differences in BP made interpretation of the
secondary endpoints difficult. For example, the rate of MI was
4.8% with valsartan versus 4.1% with amlodipine (p = 0.02).
The rate of hospitalization for HF with valsartan was less than
with amlodipine. Of importance, there was a 23% risk reduction
in new-onset diabetes with the ARB (13.1% incidence with
valsartan, 16.4% with amlodipine, p<0.00001). This finding
confirmed the observation from the LIFE studies that ARBs are
associated with a reduction in new-onset diabetes.
In summary, despite the equivalency of the primary
endpoint, VALUE clearly showed the importance of aggressive
initial antihypertensive therapy, with study data showing
achieved BP at 1 month and 6 months was predictive of future
cardiovascular events.
Conclusions
Effective lowering of blood pressure causes a highly
significant risk reduction for stroke and CHD. All scientific
evidence favours an aggressive approach to treating
hypertensive patients. In the megatrials LIFE, ALLHAT, ANBP-
2, VALUE, HOPE12 and the cardiological trial EUROPA, 13 large
reductions in event rates were seen with relatively small BP
reductions. Quite simply, the lower the blood pressure, the
better the prognosis, just as holds true for cholesterol levels.
With regards to application of guidelines, I favour the definition
of hypertension from JNC 7, adding the risk profiling set out by
the ESH-ESC guidelines, and leaving the drug selection to the
physician. Despite the recommendation of the JNC 7 guidelines
to initiate therapy with a thiazide diuretic, it is worth noting
that much of this recommendation was based on analysis of
secondary endpoints (considered soft data) in ALLHAT. To my
mind, ACE- inhibitors and ARBs are at least as equally effective
as the other classes of antihypertensive drugs on major
cardiovascular events and, furthermore, appear to have benefits
beyond BP lowering. However, it appears that these drugs acting
on the RAS lower the BP more slowly, and therefore adding a
diuretic very early on is probably indicated. Ultimately, however,
only a thorough and comprehensive assessment of a drug’s risk
and benefits in a given patient will allow us to optimize the
treatment of hypertensive cardiovascular disease.
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